Researchers at the Johns Hopkins Bloomberg—Kimmel Institute for Cancer Immunotherapy developed a new way to use bioinformatics as a gathering tool to determine how a patient’s immune system responds to immunotherapy and recognizes its own tumor.
The Cancer Letter’s most recent cover story featured an in-depth Q&A with Anthony G Letai, director of the National Cancer Institute.
